SSP-002358
Phase 2Small molecule
TakedaSSP-002358 is one of 47 small molecule programs targeting Gastroesophageal Reflux Disease. It is currently in Phase 2.
1
Indications
2
Total Trials
0
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
80 competitors in Gastroesophageal Reflux Disease
#DrugCompanyPhaseTrials
1Protonix
WWyeth-Lederle Vaccines
Approved
Aciphex
Akero TherapeuticsApproved
Prevacid
TakedaPhase 3
Alka-Seltzer
AAbbott
Approved
Rabeprazole ER
EisaiPhase 3
Zantac 150
CChattem
Phase 3
Pulmicort
SSalix
Phase 3
Esomeprazole Mg
AstraZenecaPhase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
DWP14012
Daewoong Pharmaceutical Co. LTD.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SSP-002358. EMBL-EBI & Wellcome Sanger Institute.
- [4]